Deep search
Profile Picture
  • All
  • Search
  • Images
  • Videos
  • Maps
  • News
  • Copilot
  • More
    • Shopping
    • Flights
    • Travel
    • Hotels
  • Notebook
  • Top stories
  • Sports
  • U.S.
  • Local
  • World
  • Science
  • Technology
  • Entertainment
  • Business
  • More
    Politics
  • Any time
    • Past hour
    • Past 24 hours
    • Past 7 days
    • Past 30 days
  • Best match
    • Most recent

News

FDA approves Yeztugo

CNBC on MSN · 15h
Gilead Sciences CEO on FDA approval of Yeztugo: A milestone moment in the history of HIV
Gilead Sciences chairman and CEO Daniel O’Day joins 'Squawk Box' to discuss the FDA approval of the company's HIV prevention medication, how the twice-yearly antiviral drug Yeztugo works, the importance of preventive medicine,
The Jerusalem Post on MSN · 2d
FDA approves Yeztugo: Gilead's new twice-yearly HIV prevention injection
He affirmed that the new drug "could take the epidemic to the history books," according to Mother Jones.Yeztugo, based on the molecule lenacapavir, offers a more effective and less invasive prevention method,
Infectious Disease Advisor · 14h
Twice-Yearly HIV-1 PrEP Yeztugo Gets FDA Approval
The FDA has approved Yeztugo for PrEP to reduce the risk of sexually acquired HIV-1 in adults and adolescents weighing at least 35kg.
5h
FDA approves first twice-yearly HIV prevention shot
Yeztugo showed promising results in clinical trials. One study involving women in Africa reported 100% efficacy, with zero ...
KSL
6h
FDA approves HIV drug based on University of Utah biochemist's findings
Utah biochemist Wesley Sundquist has achieved yet another milestone with the Food and Drug Administration approval of an ...
WAPT on MSN4d
Twice-a-year HIV prevention shot Yeztugo could be a game changer for Jackson and beyond
The FDA has approved Yeztugo, the first long-acting injectable PrEP shot, which could significantly impact HIV prevention ...

Some results have been hidden because they may be inaccessible to you

Show inaccessible results
Feedback
© 2025 Microsoft
  • Privacy and Cookies
  • Legal
  • Advertise
  • About our ads
  • Help
  • Feedback
  • Your Privacy Choices
  • Consumer Health Privacy